Andropenis informazioni & dimostrazioni Vedere i risultati & Calcolare la vostra futura lunghezza Raccomandazioni dei dottori & studi clinici Testimonianze dei nostri pazienti Compra ora il suo trattamento Andropenis Domande e risposte più frequenti circa l'Andropenis

Penile enlargement without surgery with the Andropenis Device

Scientific Research presented in the 1st Virtual Sexology and Hispanoamerican Sexual Education Congress (February -2001)
Dr. Eduardo A. Gomez de Diego „ 1998 Andrology Services ,Andromedical Clinic, Madrid (Spain)



1. Introduction:

When the human tissues are submitted to a force of traction, they react by increasing in size.

The principle of traction is applied in modern medicine, for the generation of new tissue to cover burn wounds or areas of hair loss ( placing a tissular expander underneath the normal skin ) or for the lengthening of bones.

In other cultures this principle is applied to lengthen different parts of the body like the Giraffe Women of the Paduang tribe in Birmania ; or the lengthening of the lips in certain African tribes of Africa that use wood to create traction; and in India where they hang stones on the penis of men as a form of penitence with the resulting enlargement of the organ.

Based on this principle of external traction the Andropenis® was designed . It is able to exhort a gradual traction force of 600 to 1500 grams.

The device consists of a plastic ring, where the penis is introduced and from where 2 dynamic metalic rods that originate the traction. In the superior part there is a plastic support where a silicone band holds the glans in place.


Based on our clinical experience the traction device yields the following results:

  • An increase in the length of the penis in erection and flaccidity.
  • An increase in the perimeter of the penis in erection and flaccidity.
  • This results will be analyzed statistically to be verified and quantified

2. Materials and Methods


Number of patients: 37 patients, ages between 22 and 60 years of age. These men proceed from different cities in Spain.


Selection of patients: patients included were healthy men with normal erection capabilities and without penile surgeries. Patients with penile or other diseases where excluded from the studies.


Traction device: The Andropenis®, Spanish penile traction device.


Traction Force: 600 gr during 1st month, 900 gr during 2nd month, 1100 gr durante 3th and 4th mes, and 1200 gr during 5th y 6th month.


Usage period: 10 hours a day, during every day of the month for a period of 3-6 months.




3. Results
3.1.- INCREASE IN LENGTH IN ERECTION:





  • The average increase in the length of the penis in erection by month is of 0.4726 cm. The standard deviation is of 0.1329 cm. The confidential interval of 95% is of [0.4283 ; 0.5169] which indicates a minimal gain in the population of 0.4283 cm/month.





  • Regression line is:

    DL erec = - 0.327 + 0.562 x t

    This calculation will allow us to estimate the increase in length of the penis in erection, based on the months of use of the device. There is a 57.7% variance in the increment in longitude, which is explained by the variance in the duration of treatment ( R2= 0.577 ). The other 42.3% is due to other differences innate to each individual and not relative to the duration of the treatment




    3.2.- INCREMENT IN LENGTH IN THE FLACCID STATE

  • The increment in length in the flaccid state is relative to the time of usage of the device. Such an increment is linear as shown in the graph. The longer the device is used, the greater the increase in length. The coefficient of the linear correlation between the time of usage and the increment in longitude in the flaccid state is of 0.725 ( p=0.000 ).





  • The average monthly increment in longitude of the penis in the flaccid state is 0.4834 cm and the typical deviation is 0.1983 cm. The confidence interval of 95% is of [0.4173 ; 0.5495] and indicates a minimum increase in the population of 0.4173 cm/month.





  • Regression line is:

    DL flac = - 1.300 + 0.840 x t

    This calculation allows us to estimate the increment in longitude in the flaccid state based on the months in which the device is used. There is a 52.5% variance in the increment in longitud which is explained by the variance of the duration of treatment ( R2= 0.525 ). The other 47.5% is due to other differences innates to the individual and not relative to the duration of the treatment.




    3.3.- VARIABILITY:

  • The variability in the increment in longitude in erection is different from that of flaccidity, being the difference in variance significant ( p= 0.003 ) which indicates a greater dispersion of the increases in length during flaccidity than in erection.


    3.4.- THE INCREMENT IN LONGITUDE DOES NOT DEPEND ON THE AGE:

  • A very interesting result was that the increment in longitude does not depend on the age of the patient, since the coefficient of the linear correlation is not significant ( r=0.008, p=0.961). In other words, the age of the patient does not effect the increment in longitude.




    -


  • -





    -

  • -




    3.7.- LONGITUDE INCREASE IN ERECTION STATE DEPENDING ON USE:


  • Dividing the population studied in four sub groups depending on the usage time of the Andropenis. we obtain the following results.


    Three months usage:
    The median longitude increment in erection state was 1.4118, obtaining a median growth of 10.5580% over the initial longitude. The confidence interval of 95% of the studied population was ( 1.1522; 1.6713) which shows a median minimal growth of 1.1522 cm in three months.

    Four months usage:
    The median longitude increment in erection state was 1.8462, obtaining a median growth of 14.1113% over the initial longitude. The confidence interval of 95% of the studied population was(1.5809; 2.1114) which shows a median minimal growth of 1.5809 cm in four months.



    Five months usage:
    The median longitude increment in erection state was 2.2750, obtaining a median growth of 16.6303% over the initial longitude. The confidence interval of 95% of the population studied was (1.7656; 2.7844) which shows a median minimal growth of 1.7656 cm in four months.


    Six months usage:
    The median longitude increment in erection state was 3.3333, obtaining a median growth of 27.5% over the initial longitude. The confidential interval of 95% of the population studied was (2.8162; 3.8504) which shows a median minimal growth of 2.8162 cm in six months.
    The samples corresponding to five and six months are very small which makes small intervals and less reliable.




    3.8.- DISTRIBUTION:

  • Although the variables considered in the population are not normal, the median samples, have normal distribution since the amount of the sample is greater than 20.



    3.9.- ABBREVIATIONS:

    Inc-Long-Erec
    Longitude increment in erection state
    DL erec
    Change in Longitude increment in erection state
    I.L.ERT
    Longitude increment in erection as a function of the time variable
    I.L.FLAC
    Longitude increment in flaccid state
    DL flac
    Change in Longitude increment in flaccid state
    I.L.FLT
    Longitude increment in flaccid state in function of time
    Inc-Long-Erec
    Longitude increment in erection state
    % I Long-Erec
    Longitude increment percentage in erection state.



    4. Conclusions

  • The use of the Spanish traction device (Andropenis ) will increase the length of the penis, both in the erectile and flaccid state.

  • The increase in length, both in and flaccidity, is directly proportional to the time of use.

  • The increase in length both in erection and flaccidity, does not depend on the natural size of the patient.

  • The average growth in length of the penis in cm/month in 95% of the patients was between 0.4283 and 0.5163 in erection, and between 0.4173 and 0.5495 in flaccidity.

  • The increments of change in length of the penis in erection are more uniform than those in flaccidity which tend to be more disparate .

  • The increment of change in the length of the penis in erection is not relative to the age of the patient.

  • The use of the penile traction device will increase the perimeter of the penis, both in erection and flaccidity.

  • The average growth in perimeter in cm/month in 95% of the patients was between 0.6111 and 1.0200 in erection, and between 0.6386 and 1.0425 in flaccidity. Treatment was 3-6 months duration.



    5. Anex

    PATIENT RESULTS (Using the Andropenis):

    Nombre

    Edad Inicio L-Erec1 L-Flac1 P-Erec1 P-Flac1 Meses L-Erec2 L-Flac2 P-Erec2 P-Flac2
    LAA 60 15.1.98 12.0 8.0 12.0 10.0 3.0 13.5 9.0 13.5 10.5
    EAG 37 30.1.98 14.5 8.0 12.0 8.5 4.0 16.5 9.5 13.0 10.5
    VA 27 26.11.97 16.3 10.4 13.9 10.1 3.0 17.8 12.5 14.5 11.5
    EAA 46 15.3.98 14.5 10.5 12.0 10.0 6.0 17.6 15.7 13.2 11.2
    JBV 25 27.3.98 15.0 8.0 13.0 9.0 3.0 16.6 9.5 13.3 10.5
    ABB 39 29.6.98 14.0 11.0 13.0 11.0 3.0 15.5 12.5 14.0 12.0
    CBG 37 19.1.98 12.5 6.0 12.0 9.0 4.0 14.0 8.8 12.5 9.4
    JBL 25 7.5.98 13.7 9.0 11.5 10.0 4.0 16.3 11.5 13.5 12.0
    JCB 27 19.11.97 13.0 8.0 14.5 12.0 6.0 16.4 11.1 14.2 12.2
    JJCA 33 1.6.98 10.5 4.9 11.0 9.5 3.0 12.0 5.5 11.5 9.5
    JCA 32 4.2.98 14.0 10.0 10.0 9.0 4.0 15.9 12.0 12.2 10.5
    ODV 25 4.3.98 16.5 9.5 13.0 9.7 3.0 18.0 11.0 13.3 10.0
    PDS 22 10.6.98 14.4 8.3 11.0 7.8 3.0 15.8 9.0 11.6 8.3
    AGM 41 26.11.98 13.0 9.0 11.0 10.0 4.0 15.0 9.5 11.0 10.0
    MGF 32 29.9.97 12.5 5.5 12.5 10.0 4.0 14.5 8.0 13.0 10.0
    AHM 44 5.3.98 11.5 8.0 13.0 12.0 3.0 13.0 9.5 14.0 12.0
    AAMP 37 12.3.98 12.7 7.0 10.5 7.5 3.0 14.0 9.0 11.0 9.0
    JLMO 34 30.1.98 14.8 11.0 11.0 9.3 4.0 15.8 11.0 12.7 9.3
    JAMV 41 28.7.97 17.0 10.0 14.0 12.5 5.0 19.6 12.3 15.0 13.5
    FOR 8% 9.11.97 12.5 7.0 10.0 9.0 5.0 14.5 11.0 11.0 10.5
    ROM 28 12.11.97 16.0 8.5 13.0 9.0 5.0 18.0 12.5 13.5 10.5
    JPC 33 16.1.98 13.7 7.2 12.3 10.1 3.0 16.7 8.7 13.1 10.9
    JAPG 29 4.11.97 10.0 8.0 12.0 10.0 6.0 13.5 11.5 13.0 11.0
    FPR 8% 20.3.98 10.5 7.0 12.0 10.0 3.0 11.3 7.3 12.7 10.0
    JPF 42 23.3.98 13.0 7.0 13.0 10.0 3.0 14.5 8.5 13.0 10.5
    AJRF 26 28.11.97 14.0 9.0 13.0 9.0 4.0 16.0 10.7 13.0 10.0
    ARR 58 7.10.97 11.0 7.0 11.0 9.0 3.0 12.0 8.0 12.0 10.0
    RRG 25 25.11.97 14.5 11.0 11.0 10.0 3.0 15.0 12.4 11.7 10.8
    CSM 35 24.2.98 15.0 9.0 11.0 9.0 3.0 16.5 11.0 12.0 10.0
    ASE 35 20.3.98 12.5 7.5 11.5 9.0 4.0 14.5 9.5 12.5 10.5
    ASPA 42 7.11.97 14.0 7.5 12.0 9.0 4.0 16.0 9.5 13.0 10.5
    SSF 27 15.8.97 14.5 7.0 14.5 8.0 3.0 15.9 8.0 15.0 8.7
    ISB 22 23.9.97 11.5 7.5 11.0 9.5 4.0 13.5 10.2 11.3 10.3
    FT 53 19.11.97 14.5 10.0 13.0 10.0 3.0 16.0 11.5 13.5 10.5
    EVC 24 29.12.97 11.0 7.0 11.5 9.0 5.0 13.5 9.0 12.5 10.5
    PV 33 8.10.97 12.0 8.5 15.5 13.0 4.0 13.0 9.5 16.0 13.0
    JSVS 32 24.1.98 12.0 6.0 10.5 9.0 4.0 14.0 8.5 12.5 9.5


    L-Erec1 = Length in Erection initial
    L-Flac1 = Length in Flaccidity inicial
    P-Erec1 = Perimeter in Erection initial
    P-Flac1 = Perimeter in Flaccidity inicial
    L-Erec2 = Length in Erection final
    L-Flac2 = Length in Flaccidity final
    P-Erec2 = Perimeter in Erection final
    P-Flac2 = Perimeter in Flaccidity final